How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?

Murray Brown, S Kirby, C Skedgel, J D Fisk, T J Murray, V Bhan, Ingrid Sketris

Research output: Contribution to journalArticlepeer-review

63 Citations (Scopus)

Abstract

Our objective was to estimate the effectiveness of disease-modifying drugs (DMDs) in delaying multiple sclerosis (MS) disability progression in relapsing-onset (R-onset) definite MS patients under "real-world" conditions.
Original languageEnglish
Pages (from-to)1498-507
Number of pages10
JournalNeurology
Volume69
Issue number15
DOIs
Publication statusPublished - 9 Oct 2007

Keywords

  • Adult
  • Antirheumatic Agents
  • Clinical Trials as Topic
  • Cohort Studies
  • Data Interpretation, Statistical
  • Databases as Topic
  • Disability Evaluation
  • Disease Progression
  • Female
  • Humans
  • Male
  • Middle Aged
  • Models, Statistical
  • Multiple Sclerosis, Chronic Progressive
  • Multiple Sclerosis, Relapsing-Remitting
  • Nova Scotia
  • Secondary Prevention
  • Treatment Outcome

Cite this